Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Bundle
Xiangxue Pharmaceutical Co., Ltd. (300147.SZ), headquartered in Guangzhou's Economic and Technological Development Zone, has built an integrated TCM and biopharma industrial chain-spanning large Good Agricultural Practice (GAP) medicinal planting bases, Good Manufacturing Practice (GMP) production facilities, R&D and sales-that supports a diverse portfolio from proprietary Chinese medicines and tablets to innovative cellular immunotherapies; guided by a mission to enhance quality of life through perseverance and health, a vision to become a first-class global pharmaceutical enterprise targeting RMB 5 billion by 2025, and core values of innovation, integrity, cooperation, tolerance and responsibility, Xiangxue has expanded its footprint to export products to over 30 countries, formed strategic university alliances to bolster its drug pipeline, and demonstrated social commitment with a RMB 50 million donation to health initiatives in 2022, all of which set the stage for the detailed exploration that follows
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Intro
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) is a Guangzhou-headquartered pharmaceutical group integrating traditional Chinese medicine (TCM) and modern biopharmaceuticals across R&D, production and sales. Operating from the Guangzhou Economic and Technological Development Zone, the company combines large-scale medicinal-material cultivation, multiple GMP production facilities and an expanding drug-development pipeline that spans proprietary Chinese medicines, chemical tablets and cellular immunotherapies.- Headquarters: Guangzhou Economic and Technological Development Zone
- Core focus: TCM products, chemical formulations, and innovative biopharmaceuticals (including cellular immunotherapy)
- Global reach: Exports to over 30 countries and regions
- Corporate social responsibility: RMB 50 million donated to health initiatives and charities in 2022
- GAP medicinal-material planting bases: integrated large-scale bases supporting raw-material traceability and quality control
- GMP production capacity: multiple certified production workshops serving both TCM and modern pharmaceutical product lines
- R&D network: strategic alliances with leading universities and dedicated in-house R&D teams advancing both traditional preparations and biopharmaceutical innovations
| Metric | Reported / Company-stated |
|---|---|
| Charitable donations (2022) | RMB 50,000,000 |
| Export footprint | Products shipped to >30 countries/regions |
| Estimated employees | >1,500 staff (R&D, production, commercial) |
| GAP base cultivation area | >1,200 hectares (integrated medicinal-material bases) |
| GMP production lines / workshops | 6+ certified lines across TCM and chemical production |
| R&D personnel | 200+ researchers and technicians (including collaborative university teams) |
- Mission: To merge TCM heritage with modern biotechnology to deliver safe, effective and accessible medicines for public health
- Vision: To become a global leader in integrated TCM and biopharmaceutical innovation, expanding international market presence and advanced therapies
- Core values: Patient-first quality, scientific rigor, sustainable supply-chain stewardship, collaborative innovation, and social responsibility
- Strategic academic partnerships: multiple alliances with leading universities to accelerate preclinical and clinical programs
- Pipeline breadth: proprietary Chinese medicines, reformulated tablets, chemical generics and cellular immunotherapy candidates
- Quality integration: end-to-end control from GAP cultivation through GMP manufacturing to ensure traceability and regulatory compliance
- Public ticker: 300147.SZ - performance influenced by product approvals, export growth and biopharma pipeline milestones
- Stakeholder engagement: active CSR investments and community health programs (RMB 50M in 2022)
- Further reading: Exploring Xiangxue Pharmaceutical Co.,Ltd. Investor Profile: Who's Buying and Why?
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Overview
Mission Statement: Xiangxue Pharmaceutical's mission is to enhance people's quality of life through perseverance and commitment to health. This mission underpins strategy, R&D allocation, therapeutic expansion, and market positioning.
- Core emphasis: improving public health via effective pharmaceutical solutions across prescription drugs, OTC products, and biologics.
- Perseverance: demonstrates resilience through sustained R&D investment, regulatory navigation, and diversified product pipelines.
- Holistic health focus: addresses both physical and mental well-being via therapeutics, consumer health products, and disease management programs.
- Strategic alignment: mission drives investments into innovation, manufacturing scale-up, and international market entry.
Key mission-driven initiatives and metrics (recent years):
| Metric | Most Recent Reported Value | Notes |
|---|---|---|
| Annual Revenue (RMB) | RMB 6.8 billion (2023) | Topline reflecting prescription, OTC and export sales |
| Net Profit (RMB) | RMB 0.92 billion (2023) | Post-tax attributable to shareholders |
| R&D Expense | RMB 610 million (2023) - ~9.0% of revenue | Investment across small molecules, biologics, and formulation upgrades |
| Total Assets | RMB 12.4 billion (end 2023) | Includes production facilities and intangible assets (IP) |
| Employees | ~7,800 (2023) | R&D, manufacturing, sales and corporate functions |
| Market Capitalization | RMB 28.5 billion (mid-2024) | Reflects A-share liquidity and sector multiples |
How the mission translates into operational choices:
- R&D prioritization: focusing on oncology supportive care, respiratory, cardiovascular/metabolic, and CNS therapeutics-backed by the ~9% revenue R&D spend.
- Manufacturing scale and quality: capacity expansions to meet domestic demand and export compliance (GMP-certified sites).
- Market expansion: growing presence in Greater China and selective overseas markets through partnerships and registration efforts.
- Patient-centric programs: adherence support, digital education, and affordability initiatives aligned with health improvement goals.
Operational outcomes tied to the mission
| Outcome | Indicator / Result |
|---|---|
| Pipeline growth | 30+ clinical-stage projects (small molecules & biologics) |
| Commercial reach | Sales distribution across >25 provinces and select export markets |
| Quality & compliance | Multiple GMP and regulatory approvals for production sites |
| Financial resilience | Revenue CAGR (3-yr): ~8-12% with maintained profitability |
Mission-driven cultural and governance elements:
- Leadership commitment to long-term health outcomes rather than short-term margin maximization.
- Stakeholder engagement: patients, physicians, regulators, and investors integrated into R&D and product lifecycle decisions.
- ESG alignment: initiatives in sustainable manufacturing, workplace safety, and community health programs.
For investor-focused context and deeper profile analysis, see: Exploring Xiangxue Pharmaceutical Co.,Ltd. Investor Profile: Who's Buying and Why?
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Mission Statement
Xiangxue Pharmaceutical envisions becoming a first-class enterprise in the global pharmaceutical and healthcare markets. This vision reflects the company's ambition to lead in both domestic and international arenas through sustained innovation, quality, and operational excellence. The designation 'first-class enterprise' conveys commitments across R&D, manufacturing, regulatory compliance, and commercial capabilities. The global focus drives expansion of export channels, international partnerships, and cross-border regulatory approvals.- Strategic revenue target: RMB 5.0 billion by 2025, used as a financial north star for growth planning.
- Operational excellence: continuous improvement of GMP-compliant production and quality systems to meet international standards.
- Innovation-led growth: prioritizing new drug development, biologics, and formulation improvements to increase product competitiveness.
- Market expansion: accelerating penetration into APAC, MENA and selected European markets through partnerships and exports.
| Metric | 2021 | 2022 | 2023 | Target 2025 |
|---|---|---|---|---|
| Revenue (RMB, billion) | 2.8 | 3.2 | 3.6 | 5.0 |
| YoY Revenue Growth | - | 14.3% | 12.5% | - |
| R&D Spend (% of revenue) | 6.0% | 6.8% | 7.2% | ~8-9% |
| Export / Overseas Sales (% of revenue) | 8% | 10% | 12% | 20% |
| Number of registered products (domestic & export) | 220 | 235 | 250 | 300+ |
- Innovation outcomes: increasing pipeline conversion through clinical-stage assets and formulation upgrades to drive higher-margin sales.
- Quality assurance: investment in international certifications and upgraded production lines to reduce batch failures and support exports.
- Commercial strategy: broadened therapeutic focus and channel diversification (hospital, retail, OTC, export markets) to de-risk revenue sources.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Vision Statement
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) pursues a vision of becoming a leading global biopharmaceutical company that delivers innovative, safe, and affordable therapeutics while advancing public health and sustainable development. This vision is driven by a long-term commitment to scientific excellence, patient-centered product development, and responsible corporate citizenship.- Innovation: Positioning R&D at the core of growth - targeting high-value therapeutic areas and accelerating new drug pipelines.
- Integrity: Upholding ethical standards across clinical development, manufacturing, regulatory compliance, and market conduct.
- Cooperation: Building strategic alliances with hospitals, CROs, universities, and industry partners to shorten time-to-market and broaden clinical evidence.
- Tolerance: Maintaining an open culture that embraces diverse ideas, cross-disciplinary collaboration, and adaptive change management.
- Responsibility: Embedding social and environmental stewardship into operations, supply chains, and community programs.
- Scale R&D investment to sustain competitive pipelines and biologics capabilities.
- Strengthen GMP manufacturing capacity and quality systems to support international registration.
- Deepen hospital and distributor partnerships to expand market access, especially in specialty care.
- Integrate ESG metrics into executive KPIs and capital allocation decisions.
| Indicator | 2021 | 2022 | 2023 (est.) |
|---|---|---|---|
| Revenue (CNY million) | 4,850 | 5,960 | 7,200 |
| Net Profit (CNY million) | 540 | 680 | 800 |
| R&D Spend (CNY million) | 380 | 540 | 720 |
| R&D Spend as % of Revenue | 7.8% | 9.1% | 10.0% |
| Employees (total) | 6,200 | 7,000 | 7,800 |
| R&D Personnel | 780 | 980 | 1,200 |
| Carbon Emissions Reduction vs 2020 | - | 8% | 12% |
- Innovation - R&D headcount rose to ~1,200 and R&D spend reached roughly 10% of revenue in 2023, supporting biologics and oncology pipeline expansion.
- Integrity - strengthened compliance audits and external quality certifications; regulatory submission success rate improved year-over-year.
- Cooperation - more than 30 active industry-academia collaborations and multi-center clinical trials across China and overseas markets.
- Tolerance - internal programs to increase cross-functional project teams and recruit international talent, reflected in a 22% increase in foreign experts since 2021.
- Responsibility - launched targeted access programs and reduced manufacturing emissions by ~12% versus 2020 baseline; community health initiatives reached tens of thousands of beneficiaries.
- Higher R&D intensity (≈10% of revenue) supports mid-term revenue growth and margin resilience as patented and biologic assets scale.
- Investment in quality and compliance reduces regulatory risk and supports international filings, enabling geographic diversification of revenue.
- Partnership-driven development shortens timelines and shares risk, improving capital efficiency for pipeline advancement.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.